Evidence map›Paper›PMID 37024692›Full record

ArticleMethods in molecular biology (Clifton, N.J.)2023

Luciferase-Based High-Throughput Screen with Aspergillus fumigatus to Identify Antifungal Small Molecules.

Timothy J Opperman, Sourabh Dhingra, Cecilia Gutierrez-Perez, Steven M Kwasny, Robert A Cramer

Open access · greenAbstract read
In one paragraph

Article in Methods in molecular biology (Clifton, N.J.), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
3.5field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Recent developments inMicrobiology and molecular biology reviews : MMBR · 2025
    Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Timothy J OppermanMicrobiotix Inc., Worcester, MA, USA.
Sourabh DhingraDepartment of Microbiology and Immunology, Geisel School of Medicine at Dartmouth, Hanover, NH, USA.
Cecilia Gutierrez-PerezDepartment of Microbiology and Immunology, Geisel School of Medicine at Dartmouth, Hanover, NH, USA.
Steven M KwasnyMicrobiotix Inc., Worcester, MA, USA.
Robert A CramerDepartment of Microbiology and Immunology, Geisel School of Medicine at Dartmouth, Hanover, NH, USA. robert.a.cramer.jr@dartmouth.edu.
Dartmouth College · USMicrobiotix (United States) · US

Funding

Regulation of Cryptosporidium DevelopmentP20GM146584 · NIGMS · CLEMSON UNIVERSITY · PI JAMES Culvin MORRIS · 2022 to 2026
$13.5M
Overcoming Emerging Aspergillus fumigatus Azole Resistance Via Protease InhibitionR33AI140878 · NIAID · DARTMOUTH COLLEGE · PI CRAMER, ROBERT ANDREW · 2021 to 2023
$1.3M
Overcoming Emerging Aspergillus fumigatus Azole Resistance Via Protease InhibitionR21AI140878 · NIAID · DARTMOUTH COLLEGE · PI CRAMER, ROBERT ANDREW · 2019 to 2020
$433k
NIAID NIH HHS R21 AI140878NIAID NIH HHS R33 AI140878NIGMS NIH HHS P20 GM146584
6 · The paper itself

Abstract

Only three classes of contemporary antifungal drugs are routinely utilized in the clinic against filamentous fungal pathogens such as Aspergillus fumigatus. High-throughput phenotypic screens to identify small molecules with activity against filamentous fungi remain challenging due to the hyphal, biofilm-like growth morphology of these important organisms. In this chapter, we describe a protocol for utilizing a bioluminescent A. fumigatus strain for identifying small molecules that potentiate the activity of the triazole antifungal drug fluconazole. The assay holds great promise for identifying small molecules with activity against filamentous fungal pathogens.

Indexed as

Antifungal AgentsAspergillus fumigatusFungiHyphaeMicrobial Sensitivity TestsTriazolesAntifungal AgentsTriazolesAntifungalAspergillus fumigatusAssay developmentFilamentous fungiHigh-throughputLuminescencePhenotypic screenSmall molecules

Identifiers

PMID37024692
PMCPMC12053524
OpenAlexW4362682854

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.